盐酸替罗非班对冠心病治疗的临床效果分析

Clinical effect analysis of tirofiban hydrochloride in the treatment of coronary heart disease

目的分析和探讨盐酸替罗非班对冠心病治疗的临床效果。方法 120例冠心病患者根据随机数字表法分为试验组和对照组,各60例,对照组采用经皮冠状动脉介入治疗(PCI)术中应用低分子肝素进行治疗,试验组采用PCI术中应用低分子肝素及盐酸替罗非班进行治疗。比较治疗后两组患者的临床效果和不良反应。结果治疗后,试验组显效56例(93.3%)、有效3例(5.0%)和无效1例(1.7%);而对照组则分别是19例(31.7%),30例(50.0%)和11例(18.3%);治疗总有效率试验组为98.3%,对照组总有效率为81.7%,试验组临床效果更好(P<0.05);且试验组不良事件发生率(心肌梗死、少量出血、顽固缺血等)明显低于对照组(P<0.05)。结论对冠心病患者采用PCI术中应用低分子肝素及盐酸替罗非班进行治疗的临床效果确切,不良事件发生率低,患者及家属均满意,推荐广泛应用于临床。

Objective To analyze and explore the clinical effect of tirofiban hydrochloride in the treatment of coronary heart disease.Methods A total of 120 coronary heart disease patients were divided into experimental group and control group by random number table, and each group contained 60 cases. The control group received low molecular heparin for treatment during percutaneous coronary intervention （PCI）, and the experimental group received additional tirofiban hydrochloride for treatment during PCI. The comparison was made between the clinical effects and adverse reactions of the two groups after treatment.Results After treatment, the excellent effective cases in the experimental group were 56 （93.3%）, effective cases were 3 （5.0%）, and ineffective cases were 1 （1.7%）. Those in the control group were respectively 19 （31.7%）, 30 （50.0%）, and 11 （18.3%）. The total effective rate of the experimental group was 98.3%, and that of the control group was 81.7%. The experimental group had better clinical effect （P〈0.05）, and less incidence of adverse reactions （myocardial infarction, few hemorrhage, persistent ischemia, etc） than the control group （P〈0.05）.Conclusion The application of low molecular heparin and tirofiban hydrochloride during PCI has precise effect in treating coronary heart disease, with low incidence of adverse reactions and wide satisfaction. This method is worth widely clinical application.